on Sandoz Group AG (isin : CH1243598427)
Sandoz Secures EU Approval for Ondibta® in Diabetes Treatment
On January 14, 2026, Sandoz Group AG announced the European Commission's approval for Ondibta® (insulin glargine). This biosimilar offers treatments akin to the reference medicine, Lantus® SoloStar®. Approved for all age groups starting from two, it matches the safety and efficacy of its reference.
Ondibta®, developed by Gan & Lee Pharmaceuticals, is slated for a 2027 launch. Its entry is expected to boost insulin access, offering affordable treatment options across Europe. This development is a strategic step for Sandoz, aligning with its aim to make impactful biologic medicines accessible.
Diabetes remains a critical global health issue, affecting millions and escalating healthcare costs. Sandoz's latest approval not only reinforces its market position in diabetes care but also highlights its leadership in biosimilars.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Sandoz Group AG news